Bay Area's Pionyr Immunotherapeutics Scores $62M to Push Anti-Tumor Tech Towards Clinic Post author:Sam Post published:December 12, 2017 Post category:BioPharma Pionyr was founded in 2015 by a UCSF professor and a Genentech alum. Source: BioSpace You Might Also Like Exelixis Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update February 27, 2017 FDA Accepts GW Pharma's Epidiolex NDA With Priority Review for Lennox-Gastaut Syndrome and Dravet… December 27, 2017 4 Biotech Stocks Worthy Enough to be Brokers' Favorites February 6, 2017
Exelixis Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update February 27, 2017
FDA Accepts GW Pharma's Epidiolex NDA With Priority Review for Lennox-Gastaut Syndrome and Dravet… December 27, 2017
